2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis

H. Jack West, MD, Founder, President and CEO

Apologies for the long wait since our own Dr. Weiss's upbeat and thoughtful review of the leading stories about lung cancer in 2011.  Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we've broken that up into several short pieces that cover a few highlights at a time.  In fact, we're going to make an effort to have podcasts shorter and easier to digest in the future.  

The first part is on EGFR-based therapies, including the EURTAC trial of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) vs. standard doublet chemo in a European, EGFR mutation-positive patient population, followed by work on EGFR TKI/monoclonal antibody combinations: one being the single arm afatinib/Erbitux (cetuximab) for patients with acquired resistance after a good response to earlier EGFR TKI therapy, and the second being Tarceva with either the c-MET antibody MET-MAb or placebo.  

Here's the audio and video versions of the podcast, along with the transcript and figures for this portion of the program.

[powerpress]

Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Audio Podcast

Dr. Weiss Lung Cancer Highlights  2011 Pt 1 EGFR Axis Transcript

Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Figs

We'll be putting out more pieces of this every few day or two, so look for the next part very soon.  Thanks to Dr. Weiss, and also to LUNGevity Foundation for partnering with us to make this program possible.

Video Language: 

Comments

+++++++++++++++++++++++++
Dr. Howard (Jack) West
Medical Oncologist
City of Hope Cancer Center
Duarte, CA

Founder & President
Global Resource for Advancing
Cancer Education

+++++++++++++++++++++++++
Dr. Howard (Jack) West
Medical Oncologist
City of Hope Cancer Center
Duarte, CA

Founder & President
Global Resource for Advancing
Cancer Education

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation